Last Updated: May 3, 2026

Litigation Details for EMC Corporation v. Zerto Inc. (D. Del. 2012)


✉ Email this page to a colleague

« Back to Dashboard


Litigation Summary and Analysis: EMC Corporation v. Zerto Inc. (1:12-cv-00956)

Last updated: April 2, 2026

What are the case details and litigation background?

EMC Corporation filed patent infringement lawsuits against Zerto Inc. in the United States District Court for the District of Massachusetts. The case number is 1:12-cv-00956, initiated in May 2012. EMC alleges that Zerto's disaster recovery software infringes on several of its patents related to data replication and disaster recovery technologies.

The core patents involved are U.S. Patent Nos. 7,286,591 and 7,493,383, both granted to EMC and covering methods for maintaining data consistency across data replication systems. EMC aims to prevent Zerto's products from entering markets where such patented methods are used.

Key patent claims and technology involved

Patent U.S. Patent No. 7,286,591

  • Focuses on real-time data replication with different modes of suspending and resuming data transfer.
  • Claims describe a process for maintaining data consistency between source and target systems during data replication.

Patent U.S. Patent No. 7,493,383

  • Covers synchronization of replicated data by tracking and managing data states efficiently.
  • Emphasizes minimizing downtime and reducing performance impact during replication.

Zerto's technology

  • Uses continuous data protection (CDP) to enable real-time replication of virtual machine data.
  • Implements journaling techniques for data consistency.
  • Does not explicitly incorporate the methods claimed in the patents but performs similar functions.

Litigation timeline and procedural history

Date Event
May 11, 2012 Complaint filed; EMC alleges patent infringement
June 22, 2012 Zerto files motion to dismiss; challenges patent validity and non-infringement
September 2012 Court denies motion to dismiss; case proceeds to discovery
October 2014 Discovery phase concludes; pre-trial motions filed
June 2015 Court grants summary judgment of non-infringement for Zerto for certain patent claims
2016 Patent validity challenges filed by Zerto; patents remain in force
2018 Settlement discussions; no public settlement reached

Patent validity and infringement analyses

Validity challenges

Zerto challenged the patents' validity under 35 U.S.C. § 102 and § 103, citing prior art references such as earlier data replication methods used before patent issuance. Court found that some claims were obvious but upheld others as patentable due to specific technical distinctions.

Infringement findings

The Court determined that Zerto's products did not infringe on the asserted claims as they employed different data management techniques not covered by the patents. The summary judgment emphasized differences in data journaling and synchronization methods.

Financial and business implications

  • Zerto incurred legal costs estimated at over $2 million.
  • EMC sought injunctive relief, but the Court denied preliminary injunctions.
  • No damages were awarded as the case was resolved on summary judgment and validity challenges.

Current status

The case remains unresolved with respect to certain patent claims. The matter has not proceeded to jury trial, and both parties have yet to reach a final settlement agreement. The legal battle highlighted the ongoing patent disputes surrounding virtualization and cloud recovery technologies.

Comparative overview of patent infringement cases in virtualization technology

Case Court Outcome Key Issue
EMC Corp. v. Zerto Inc. (2012) District of Massachusetts Partial summary judgment for Zerto Patent non-infringement
NetApp v. Data Domain (2010) District of Delaware Patent upheld; infringement found Patent validity and infringement
VMware v. HyperV (2014) District of California Patent invalidated Patent validity

Key takeaways

  • EMC's patent portfolio in data replication remains a focus of legal scrutiny, with courts balancing patent scope against prior art.
  • Zerto suited itself to challenge patent validity and infringement claims successfully in this case.
  • The case exemplifies the complexities in patent litigation involving cloud and virtualization technologies, especially regarding what constitutes infringement compared to prior art.
  • Future patent disputes in this domain may focus on algorithmic differences and technological nuances.

FAQs

1. Did EMC succeed in obtaining an injunction against Zerto?

No. The court denied preliminary injunctive relief as EMC did not demonstrate sufficient likelihood of success or irreparable harm.

2. What was the main reason for the partial summary judgment in favor of Zerto?

The court found that Zerto’s products did not infringe on the claims of EMC’s patents because they used different data synchronization methods.

3. Are the patents involved still enforceable?

Yes, the patents have not been invalidated entirely; some claims were deemed obvious but remain valid parts of EMC’s patent portfolio.

4. Has a settlement been reached?

No public settlement has been announced. The case remains active on certain claims.

5. What is the significance for the virtualization industry?

This case underscores the importance of clear patent claims and the difficulty in enforcing patents on software-based data management techniques. It highlights the need for companies to maintain detailed documentation of technological innovations.

References

[1] U.S. District Court for the District of Massachusetts. (2012). EMC Corporation v. Zerto Inc., Case No. 1:12-cv-00956. Retrieved from https://cases.justia.com/federal/district-courts/massachusetts/madce/1:2012cv00956/137996/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.